FDA pushes better pregnancy safety data for medicines

The FDA has updated its guidance to encourage stronger collection of pregnancy safety data for drugs and biologics. The goal is better evidence, not a new approval rule or a mandate to change treatment today.

For people who are pregnant, planning pregnancy, or breastfeeding, the update matters because many commonly used medicines still have limited human pregnancy data. That can make decisions harder for patients and clinicians.

What the FDA changed

In its May 8, 2026 guidance, the FDA says drug and biologic makers should use better methods after a product is approved to study safety in pregnancy. The agency points to pregnancy registries, real-world data, and descriptive studies as tools that can help fill evidence gaps.

The FDA also says these studies should follow established scientific standards, especially for observational research. The guidance is the agency’s current thinking; it does not create a new legal requirement by itself.

Why this is needed

The FDA says many pregnant patients may benefit from medications for chronic or new health conditions, but human pregnancy data are often limited when products first reach the market. The agency says that gap can leave clinicians and patients making decisions without enough information about possible risks to the pregnant patient or the developing fetus.

The FDA’s own pregnancy resources also note that people may need medicines for conditions such as diabetes, depression, or high blood pressure during pregnancy, which is why clearer labeling and better evidence can matter in everyday care.

Why it matters for everyday people

This is most relevant for people who take long-term medicines before pregnancy, start new treatment during pregnancy, or need to decide whether a drug should be continued after delivery. It also matters for breastfeeding decisions, since some evidence gaps extend into the postpartum period.

For patients, the practical benefit would be more informative labeling and better counseling from clinicians. For example, a pregnancy registry may eventually help show whether a medicine has a pattern of safety concerns, or whether earlier uncertainty was simply due to too little data.

What does not change today

Current prescribing still depends on individualized risk-benefit discussions with a clinician. The new guidance does not mean every medicine has new data now, and it does not mean a medication should be stopped or switched without medical advice.

The FDA also notes that pregnancy studies are often non-randomized, which means they can help answer important questions but may still leave some uncertainty about cause and effect.

What remains uncertain

It is not yet clear which products will be studied first, which study designs will produce the most useful information, or how quickly better data will appear in labels and clinical practice. The usefulness of any study will also depend on enrollment, follow-up, and whether people are able to participate in pregnancy registries.

NIH’s maternal-health research priorities, including the IMPROVE initiative, show that the broader problem is not just medication evidence, but maternal health outcomes overall. That underscores how much work still remains in pregnancy research.

What readers can do

If you are pregnant, trying to become pregnant, or breastfeeding and take a prescription medicine, ask your clinician or pharmacist:

Is there a pregnancy registry for this medicine?
What do we know, and what do we not know, about pregnancy safety?
Should this medicine be continued, changed, or monitored more closely?
Are there any warning signs that should prompt urgent care?

Do not stop or change a prescribed medicine on your own. If you have severe symptoms, such as trouble breathing, heavy bleeding, chest pain, severe headache, or decreased fetal movement later in pregnancy, seek urgent care right away.

For many families, the main value of this FDA guidance will be gradual: better evidence, clearer labels, and more informed conversations in prenatal, postpartum, and breastfeeding care.

Sources

Editorial note: Weence articles are researched from cited public-health, medical, regulatory, journal, and reputable news sources and may be drafted with AI assistance. They are checked for source support, clarity, and safety guardrails before publication.

This article is for general informational purposes only and is not medical advice. Research findings can be early or incomplete, and health guidance can change. Always talk with a qualified healthcare professional about personal symptoms, diagnosis, medications, vaccines, screenings, or treatment decisions. If you think you may have a medical emergency, call emergency services right away.